GO:0015825 L-serine transport: Genes, Functions & Methods

L-serine is a non-essential amino acid that serves as a precursor for proteins, nucleotides, phospholipids, and the neuromodulator D-serine. Although many cells can synthesize L-serine de novo from glycolytic intermediates, rapidly proliferating cells and certain neuronal populations rely on transporter-mediated uptake from the extracellular environment. The Gene Ontology term GO:0015825 L-serine transport captures the biological process by which L-serine is moved across membranes, a function critical for metabolic homeostasis and cell survival. Understanding this process is important because dysregulated serine transport is increasingly linked to cancer metabolism, neurological disorders, and metabolic disease. Research over the past decades has identified multiple transport systems for L-serine, including sodium-dependent and sodium-independent carriers belonging to the solute carrier (SLC) superfamily. In cancer cells, the glutamine transporter ASCT2 (SLC1A5) was shown to be a major contributor to serine uptake, highlighting the interplay between amino acid transporters and metabolic reprogramming. In mitochondria, SFXN1 mediates L-serine import required for one-carbon metabolism, linking cytoplasmic serine availability to mitochondrial folate-dependent processes. These findings underscore that L-serine transport is not a single protein event but a coordinated network of transporters with distinct subcellular localizations and kinetic properties. For researchers, GO:0015825 provides a standardized framework to annotate genes and proteins involved in L-serine movement, enabling comparative genomics, functional enrichment, and systems-level analysis of amino acid transport. This article reviews the definition, molecular players, regulatory mechanisms, disease relevance, and experimental strategies for studying L-serine transport, with a focus on CRISPR-based models and functional genomics approaches.

GO:0015825 L-serine transport is defined as the directed movement of L-serine, the L-enantiomer of serine, into, out of, or within a cell or between cells, mediated by specific transporter proteins. This process encompasses transport across the plasma membrane, mitochondrial membrane, and other organellar membranes, and can be sodium-dependent or sodium-independent depending on the carrier. The term is a child of amino acid transport and is distinct from transport of D-serine, which is a separate biological process.

L-serine transport is fundamental to cellular metabolism because it controls the intracellular availability of a key amino acid used for protein synthesis, nucleotide biosynthesis, methylation reactions, and antioxidant defense. In cancer, upregulated serine uptake supports rapid proliferation and survival under metabolic stress. In the nervous system, proper L-serine transport is required for neuronal development and function, and its disruption contributes to severe neurodevelopmental disorders. Thus, understanding GO:0015825 has broad implications for cancer biology, neuroscience, and metabolic medicine.

The following genes encode transporters and related proteins that directly mediate or regulate L-serine transport across membranes.

L-serine transport is regulated at multiple levels, including transcriptional control by amino acid availability, mTORC1 signaling, and stress-responsive transcription factors. For example, the expression of SLC1A5 and other amino acid transporters is influenced by MYC and ATF4, which coordinate metabolic adaptation to nutrient stress. In cancer cells, oncogenic signaling pathways upregulate serine transporters to meet increased biosynthetic demands. Additionally, the activity of transporters can be modulated by post-translational modifications and interacting proteins, such as the association of SLC7A5 with SLC3A2. In the brain, L-serine transport is regulated by neuronal activity and astrocyte-neuron metabolic coupling. These regulatory mechanisms ensure that L-serine transport matches cellular needs for protein synthesis, one-carbon metabolism, and neurotransmission.

Inborn errors in serine biosynthesis and transport cause severe neurological disorders characterized by microcephaly, seizures, and developmental delay. Mutations in genes such as PHGDH, PSAT1, and PSPH impair endogenous serine production, increasing reliance on transport. Defects in transporters like SLC1A4 can further compromise neuronal serine supply, leading to neurodevelopmental phenotypes. These disorders highlight the critical role of L-serine transport in brain development and function.

Many cancer cells depend on exogenous serine for proliferation, and upregulated serine transporters such as SLC1A5 and SLC38A2 support this demand. ASCT2 (SLC1A5) is a major contributor to serine uptake in cancer cells, and its inhibition reduces tumor growth in preclinical models. Phenotypic profiling of solute carriers has identified multiple transporters that contribute to serine uptake, suggesting redundancy and potential for combination targeting. Thus, L-serine transport is a promising target for cancer metabolic therapy.

L-serine transport influences the availability of D-serine, a co-agonist of NMDA receptors, which is implicated in schizophrenia and neurodegenerative diseases. Astrocytic L-serine export and neuronal uptake are essential for D-serine synthesis, and disruptions in this pathway may contribute to NMDA receptor hypofunction. Additionally, defects in serine transport can exacerbate oxidative stress and neurodegeneration.

Metabolic pathways controlling skin homeostasis and inflammation involve amino acid transport, including L-serine transport, which supports keratinocyte proliferation and immune cell function. Targeting serine transport may modulate inflammatory responses in skin diseases.

CRISPR-based knockout screens and phenotypic profiling of solute carriers are powerful approaches to identify genes required for L-serine transport. These screens can systematically test the contribution of each SLC family member to serine uptake and cell fitness under serine-limited conditions. Such studies have revealed that multiple transporters contribute to serine uptake, with context-dependent essentiality.

Stable isotope tracing with 13C-labeled serine or glucose allows quantification of serine transport and its contribution to one-carbon metabolism. By measuring isotopic labeling in downstream metabolites such as glycine, formate, and nucleotides, researchers can assess the role of specific transporters in metabolic flux. This method is particularly useful for studying mitochondrial serine transport via SFXN1.

Radiolabeled or fluorescent L-serine uptake assays in cells or proteoliposomes measure transport kinetics and substrate specificity. These assays can be combined with CRISPR knockout of candidate transporters to attribute transport activity to specific genes. For example, ASCT2-mediated serine uptake was demonstrated using such assays in cancer cells.

Fluorescent tagging of transporters and live-cell imaging reveal subcellular localization and trafficking of L-serine transporters. Tagged knock-in models enable visualization of endogenous transporters at physiological expression levels. Imaging can also be used to monitor serine distribution using genetically encoded fluorescent sensors.

Researchers studying L-serine transport-related genes often need to determine whether a candidate gene is causally involved in serine uptake, metabolism, or disease. EDITGENE provides comprehensive CRISPR-based services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support, enabling rigorous functional studies of GO:0015825 and its associated genes.

GO:0015825 L-serine transport is a fundamental biological process that controls the availability of a key amino acid for protein synthesis, one-carbon metabolism, and neurotransmission. Dysregulation of L-serine transport contributes to cancer, neurodevelopmental disorders, and other diseases, making it an important area of research. Advances in CRISPR-based models and functional genomics are enabling precise dissection of the transporters and regulatory mechanisms involved, paving the way for new therapeutic strategies.